AzTrials
AzTrials

HIVNCT05090150

The SMART ART Study

A study testing Home delivery of ART, Smart Lockers (Pele boxes) and Best clinic practices + conditional lottery incentives in people with HIV and ART, run by Massachusetts General Hospital at 1 site in South Africa.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators propose A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa- the SMART ART study-a randomized study to test adaptive ART delivery for persons with detectable viral load and/or not engaged in care.The types of differentiated service delivery… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
HIV, ART
What is being tested?
Home delivery of ART, Smart Lockers (Pele boxes) and Best clinic practices + conditional lottery incentives
Could I receive a placebo?
No, everyone receives an active treatment
How many people
874 participants
Where
1 siteSouth Africa
Study dates
2 Nov 2021to 3 Jul 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Must be 18 years or older
  • Able and willing to provide informed consent for study procedures
  • Must self report that they will reside in the study community for the duration of follow-up
  • Living with HIV and eligible for ART by national guidelines, have a detectable viral load greater than the lower limit of detection and/or not engaged in care, and are stable clinically (CD4>100 cells, no moderate/severe screening laboratory abnormalities for kidney function i.e. eGFR >50 mL/min/1.73m2, not receiving treatment for active tuberculosis or other opportunistic infections).

Who cannot join

  • There are no separate exclusion criteria.

Trial locations and contacts

1 site in 1 country.

South Africa1 site
  • Human Sciences Research Council Sweetwaters

    Sweetwaters, KwaZulu-Natal

Other trials in South Africa

About this study

Official title: A Sequential Multiple Assignment Randomized Trial of Scalable Interventions for ART Delivery in South Africa: the SMART ART Study

The investigators propose A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa- the SMART ART study-a randomized study to test adaptive ART delivery for persons with detectable viral load and/or not engaged in care.The types of differentiated service delivery (DSD) that will be examined in this study are incentives, community-based ART, and home delivery. The study plans to enroll up to 900 participants-people living with HIV and who are eligible for ART and living in KwaZulu-Natal, South Africa. The study aims to maximize the proportion of ART eligible persons living with HIV who achieve viral suppression at 18 months. The study will also evaluate the preferences of clients and providers for differentiated service delivery, and evaluate the cost effectiveness of adaptive HIV treatment for those who are not engaged in care.

Read the detailed description

Of the 8 million people in South Africa living with HIV, only 56% are on antiretroviral therapy (ART), and 45% are virally suppressed, substantially below the UNAIDS goal of 73%. Detectable viral load results in HIV-associated morbidity and mortality, and HIV transmission. Patient barriers to care, such as missed wages, transport costs, and long wait times for clinic visits and ART refills, are associated with detectable viral load. HIV differentiated service delivery (DSD) has simplified ART delivery: incentives, multi-month scripts, fast-track ART, and community or home ART delivery motivate clients, reduce the frequency of clinic visits, and decongest clinics. DSD is standard for clients who achieve viral suppression and engage in care; however, DSD needs adaptation to serve clients who are not succeeding. Indeed, persons who are not engaged in care arguably need simplified, client-centered approaches even more than those who can successfully engage.

A suite of adaptive DSD strategies, including incentives strategies, community-based ART, and home delivery, have been tested among stable clients with viral suppression. Lottery incentives effectively change short-term behavior, increasing ART initiation.Community-based and home ART delivery increase ART coverage and simplify ART access overcoming clinic barriers11. For stable clients, these DSD activities are as effective as clinic-based care in terms of achieving and maintaining viral suppression, although among stable clients they have not shown superiority in viral suppression or cost savings. In contrast, DSD has the potential to improve rates of viral suppression and retention in care and save costs among persons not engaged in care. There is great potential that DSD systems can be client-responsive and system-efficient for subgroups requiring additional services, matching services with client needs. A sequential, comprehensive package of DSD approaches, with each step increasing the intensity of service provision - adaptive DSD - has not been tested to determine the proportion and characteristics of persons who would achieve viral suppression and retention in care and to estimate the cost-effectiveness and budget impact.

To increase population level viral suppression, persons with detectable viral load need responsive DSD interventions. A Sequential Multiple Assignment Randomized Trial (SMART) design facilitates evaluation of a stepped, adaptive approach to achieving viral suppression with 'right-sized' interventions. The investigators are an experienced team and propose to build on the strong partnerships to sequentially test adaptive DSD strategies for persons with detectable viral load and/or not engaged in care: incentives, community-based ART, and home delivery. As the Center for Community Based Research, the investigators maintain strong connections with stakeholders including department of health, traditional leaders and ward counsellors throughout the Greater Edendale Area (GEA) and the Vulindlela sub-district of the uMgungundlovu District Municipality. Due to the size of the recruitment target, this work will centre around the Caluza clinic but will extend into other parts of GEA and sub-district of Vulindlela over the course of recruitment. The aim is to identify the most effective and efficient HIV care delivery strategies.

Conditions
HIV, ART
Being tested
Home delivery of ART, Smart Lockers (Pele boxes), Best clinic practices + conditional lottery incentives, Best clinic practices

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Home delivery of ARTOther

    Home ART refill and monitoring, adherence support

  • Smart Lockers (Pele boxes)Other

    Decentralized ART refills and monitoring, adherence support

  • Best clinic practices + conditional lottery incentivesOther

    Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

  • Best clinic practicesOther

    Continue with best clinic practices

Study groups in NCT05090150
Study groupRoleWhat they receive
Best clinic practicesNo interventionParticipants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm)
Best clinic practices plus lottery incentivesExperimentalParticipants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm)
Receives: Other: Best clinic practices + conditional lottery incentives
Randomized from best clinic practices to smart lockersExperimentalSecond randomization into community ART through the use of smart lockers
Receives: Other: Smart Lockers (Pele boxes); Other: Best clinic practices
Randomized from best clinic practices to home deliveryExperimentalSecond randomization into home ART delivery
Receives: Other: Home delivery of ART; Other: Best clinic practices
Randomized from best clinic practices plus lottery incentives to smart lockersExperimentalSecond randomization into community ART through the use of smart lockers
Receives: Other: Smart Lockers (Pele boxes); Other: Best clinic practices + conditional lottery incentives
Randomized from best clinic practices plus lottery incentives to home deliveryExperimentalSecond randomization into home ART delivery
Receives: Other: Home delivery of ART; Other: Best clinic practices + conditional lottery incentives

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Viral suppression at 18 months

    The primary outcome is viral suppression at 18 months among the combined group of persons living with HIV who have detectable viral load and persons not engaged in care at enrollment.

    Measured: 18 months

Secondary outcomes (4)
  1. Retention in Care

    The proportion of clinical visits and medication refills missed over the last 12 months of the intervention

    Measured: 12 months

  2. Time to ART initiation

    Time to antiretroviral therapy initiation

    Measured: 6 months

  3. Engagement in care

    Proportion of people who are virally suppressed in each intervention arm

    Measured: 18 months

  4. Comparison to viral suppression and retention outcomes from similar local clinics

    Proportion of individuals who are virally suppressed who are engaged in care in intervention arms compared to local clinics

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Oct 2021
  2. Study start2 Nov 2021
  3. Primary completion3 Jul 2025
  4. Study completion3 Jul 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Sequential
Model description
Participants are first randomly assigned to two interventions:either best clinic practices or best clinic practices with a conditional lottery incentive. This stage lasts 6 months. Participants who do not meet the criteria for non-response will continue in the assigned intervention arm. Non-responders will be rerandomized to continue in the clinic intervention arm (standard of care), community ART (smart lockers), or home delivery.
Masking
None (open label)
Enrolment
874 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05090150
Sponsor's protocol ID
2022P001129
Other IDs
R01MH124465
Status last verified
Jan 2026
First submitted
16 Sep 2021
Last updated
24 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • van Heerden A, Szpiro A, Ntinga X, Celum C, van Rooyen H, Essack Z, Barnabas R. A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa: the SMART ART study. Trials. 2023 Jan 17;24(1):32. doi: 10.1186/s13063-022-07025-x.

    PubMed 36647092

Questions about this trial

What is this clinical trial studying?

A study testing Home delivery of ART, Smart Lockers (Pele boxes) and Best clinic practices + conditional lottery incentives in people with HIV and ART, run by Massachusetts General Hospital at 1 site in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Viral suppression at 18 months (time frame: 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05090150, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in